Houston health tech accelerator names annual cohort ahead of its pitch competition

female founders

Meet the female health tech founders being accelerated by Ignite Healthcare this year. Photo courtesy of Ignite

Last month, a Houston organization dedicated to supporting female founders in health care kicked off its 2023 accelerator with cohort participants from across the country.

Ignite Healthcare Network, based in Houston, is a nonprofit founded on the mission of supporting women in health care. Ignite established its 12-week accelerator program to help advance and connect female health tech founders with mentors and potential clients as their startups scale.

"We have 19 founders doing great work, and we have them matched with three to four advisors helping to mentor them," Ayse McCracken, founder and board chair of Ignite tells InnovationMap. "We also have a virtual learning program, which is new this year, and we have two sessions of those a week."

The programming is curated to tackle the health tech industry's biggest topics and provide advice for a small group of engaged startups, McCracken explains. In its fifth year now, the program has a large group of partners that are involved.

"We've had 91 companies come through our program in the last fours years," McCracken says. "They've raised over $550 million."

The cohort concludes on November 9 with the Fire Pitch Competition at the Ion, where a handful of finalists — selected by Ignite's team of mentors — will present to win the top award.

This year's cohort includes:

  • Somer Baburek, CEO and co-founder of Hera Biotech
  • Sue Carr, president and founder of CarrTech Corp
  • Suchismita Acharya, CEO, chief strategy officer, and co-founder of AyuVis
  • Asma Mirza, CEO and founder of Steradian Technologies
  • J’Vanay Santos, CEO and founder of MyLÚA Health
  • Maureen Brown, CEO and co-founder of Mosie Baby
  • Elizabeth Friedman, president and founder of Safen Medical Products
  • Meghan Doyle, CEO and co-founder of Partum Health
  • Marina Tarasova, COO and co-founder of Paloma Health
  • Melissa Bowley, CEO and founder of Flourish Care
  • Molly Hegarty, CEO and founder of Junum
  • Patty Lee, CEO and co-founder of Orbit Health
  • Piyush Modak, Vice President of R&D and co-founder of EndoMedix
  • Debbie Chen, CEO and founder of Hydrostasis
  • Rachael Grimaldi, CEO and co-founder of CardMedic
  • Rachna Dhamija, CEO of Ejenta
  • Carolyn Treviño Jenkins, CEO and co-founder of We Are Here
  • Lyn Markey, CEO and co-founder of XTremedy
  • Camille O’Malley, CTO and co-founder of XTremedy
Last year, Joanna Nathan, CEO of Houston-based Prana Thoracic, won the top award for her company.
From Your Site Articles
This month, TMCi is welcoming a slew of health tech and cancer innovators who will advance solutions in medicine over the next several months. Image via TMC.edu

TMC announces entrepreneurs, researchers joining its 2 health tech accelerators

coming soon

The Texas Medical Center has announced the latest cohorts of its two health tech accelerators.

The Texas Medical Center Innovation has named eight companies that are in the Spring 2023 Accelerator for HealthTech cohort. TMCi also announced 21 participants are set to join the 2023 Accelerator for Cancer Therapeutics cohort. Both programs connect the entrepreneurs and innovators to experts at TMC’s campuses to solve unmet clinical needs and reach the next business milestone.

“At TMC Innovation, we start with a promise of uniting cutting-edge innovators in science and medicine with the talent found at the Texas Medical Center," says Emily Reiser, associate director of TMC Innovation, in a news release. "Our 2023 cohort members are tackling some of the most critical issues we face today in healthcare.

"We are excited to welcome a new group of researchers and companies to the TMC Innovation Factory, and to work collaboratively with our new cohort members and our partners from across the Texas Medical Center," she continues.

Here's what 2023 can expect from these two program's cohorts.

TMCi HealthTech Accelerator

The six-month, twice annual HealthTech Accelerator — originally launched in 2014 with over 225 alumni companies — focuses on digital health and medical device startups. The spring cohort are addressing solutions across maternal medicine, mental health, diagnostics, patient experience, and artificial intelligence.

"Uniting talented professionals from across the globe provides a unique opportunity for innovation, creativity, and development in diverse areas of expertise," says Devin Dunn, head of the Accelerator for Healthtech at TMCi, in the release. "Our tailored program maximizes participants' experiences while determining the best match between these companies and Texas Medical Center’s network."

The cohort was selected following a November bootcamp that introduced potential startup members to the TMC and the Houston health care community.

The following companies will join the TMC this month:

  • Based in Roseville, Minneapolis, Bloom Standard is deploying the first self-driving pediatric ultrasound to earlier diagnose heart and lung conditions in primary care, remote and under-resourced settings.
  • San Francisco-based Ejenta automates remote monitoring and care using AI technology exclusively licensed from NASA. “Intelligent agents” learn from connected devices, claims and EMR data to monitor patients, predict health and to provide automated support for patients and automated workflow for clinicians.
  • Kintsugi, based in Berkley, California, is on a mission to see mental health more clearly by developing novel voice biomarker infrastructure to detect signs of depression and anxiety from short clips of free-form speech.
  • San Francisco-based Lana Health is modernizing patient experiences, across the care continuum with an end-to-end, scalable platform, enabling frictionless care transitions, high patient satisfaction, and better clinical outcomes.
  • Liberate Medical, from Crestwood, Kentucky, improves outcomes for mechanically ventilated patients using its breakthrough, non-invasive, respiratory muscle-protective, neurostimulation device, VentFree.
  • Limbix, headquartered in Palo Alto, has a mission to improve mental health with accessible technology.
  • Nua Surgical, from Galway, Ireland, Nua Surgical is an award-winning Irish start-up dedicated to innovating in women’s health.
  • Houston-based Prana Thoracic is developing solutions for the detection and intervention of early-stage lung cancer.

Accelerator for Cancer Therapeutics

The TMC has announced the 21 researchers and companies tapped to join the 2023 Accelerator for Cancer Therapeutics.

The nine-month program, funded by the Cancer Prevention and Research Institute of Texas in partnership with the Gulf Coast Consortia and the University of Texas Medical Branch, supports investigators and early-stage biotechnology companies with innovative solutions in cancer therapeutics. Participants will be mentored by a group of scientific, business, and innovation leaders to ultimately be positioned to apply for grants and pitch to investors and corporate partners to further the development of their innovative cancer solutions.

“For this third cohort, we focused on a strategic and extensive recruitment process, including the evaluation of 1,679 cancer research projects. From 56 applications, we selected 21 participants that will gain access to valuable resources, integrated training and mentorship to prepare for clinical trials,” says Ahmed AlRawi, program manager of Accelerator for Cancer Therapeutics, in the release. “Our 2023 cohort represents our most diverse cohort to date, including eight companies led by women entrepreneurs. We are excited to continue the momentum and build off the successes of our previous years.”

Forty-five participants have gone through the accelerator program since its launch in 2021, and collectively, the entrepreneurs have raised more than $90 million in funding and three projects are in the clinic.

The 2023 cohort participants are focused on a wide range of therapeutic assets, including small molecule, antibody, peptide/protein, cell therapy, and other. The 2023 cohort kicks off their nine-month program in January.

The participants include:

  1. Dr. Amit K. Tripathi – UNT-Health Science Center
  2. Dr. Darshan Gandhi (ImproveBio, LLC)
  3. Dr. Frank McKeon (Tract Pharmaceutical) – University of Houston
  4. Dr. Hemanta Baruah (Aakha Biologics)
  5. Dr. Joshua Gruber – UT-Southwestern
  6. Dr. Kyoji Tsuchikama – UT Health Science Center-Houston
  7. Dr. Maralice Conacci Sorrell – UT-Southwestern
  8. Dr. Michael Buszczak – UT-Southwestern
  9. Dr. Nadezhda (Nadia) German -Texas Tech-Lubbock
  10. Dr. Parsa Modareszadeh (HemePro Therapeutics) – UT-Dallas
  11. Dr. Robert Kruse (HydroGene Therapeutics)
  12. Dr. Xiang Zhang – Baylor College of Medicine
  13. Dr. Youngwook Won (Singular Immune, Inc.)
  14. Dr. Zhi-Ping Liu (Raphael Pharmaceutical LLC) – UT-Southwestern
  15. Dr. Jonathan Arambula (InnovoTEX Inc.)
  16. Dr. Isaac Chan – UT-Southwestern
  17. Dr. Olga Granaturova (Ruptakine Inc.) – UT Health Science Center-Houston
  18. Dr. Jim Song (Tranquility Biodesign) – Texas A&M-College Station
  19. Dr. Rosa Selenia Guerra-Resendez (Quetzal Bio, LLC) – Rice University
  20. Dr. Cassian Yee (Mongoose Bio, LLC) – UT-MD Anderson Cancer Center
  21. Dr. Manjeet Rao (Niragen, Inc.) – UT Health Science Center-San Antonio


These nine companies are headed to Houston. Photo courtesy of TMC

TMC Innovation names 9 companies to its latest bootcamp

coming soon to Hou

Nine startups hailing from as far away as Sydney, Australia, are en route to Houston to participate in a week-long program at the Texas Medical Center's Innovation Factory.

The 2022 TMCi Accelerator for HealthTech Bootcamp is looking to accelerate these startups, which specialize in health tech innovation across the spectrum — maternal medicine, mental health, diagnostics, patient experience, and artificial intelligence.

“One of the things I love about Bootcamp is the opportunity to showcase the diversity of innovation our ecosystem attracts," says Devin Dunn, head of the Accelerator for Healthtech, in a news release. "The breadth of clinical and operational expertise in our Medical Campus creates a unique learning ground, truly unmatched. Our tailored accelerator program allows for an experience that is personalized to each company’s stage, specialty and growth objectives.”

After the week at TMC, a smaller group of startups will be accepted into the TMCi Accelerator, a six-month program focused on maturing strategic relationships.

“Startup companies who are impacting the future of healthcare need clinical evidence to validate their value proposition and grow their businesses," says Emily Reiser, associate director of TMC Innovation, in the release. "Our platform at the TMC sources the best talent from around the world, performs rigorous diligence, and brings entrepreneurs together with our dedicated network to drive value for each stakeholder. We are seeing this value proposition resonate with entrepreneurs, including international companies preparing to enter the US market”

The nine startups that will be participating in the program, per the news release, include:

  • Based in Roseville, Minneapolis, Bloom Standard is deploying the first self-driving pediatric ultrasound to earlier diagnose heart and lung conditions in primary care, remote and under-resourced settings.
  • Echo IQ, headquartered in Sydney, is a screening program that applies a proprietary algorithm to produce risk assessments for patients using their echocardiographic measurements.
  • San Francisco-based Ejenta automates remote monitoring and care using AI technology exclusively licensed from NASA. “Intelligent agents” learn from connected devices, claims and EMR data to monitor patients, predict health and to provide automated support for patients and automated workflow for clinicians.
  • Kintsugi, based in Berkley, California, is on a mission to see mental health more clearly by developing novel voice biomarker infrastructure to detect signs of depression and anxiety from short clips of free-form speech.
  • San Francisco-based Lana Health is modernizing patient experiences, across the care continuum with an end-to-end, scalable platform, enabling frictionless care transitions, high patient satisfaction, and better clinical outcomes.
  • Liberate Medical, from Crestwood, Kentucky, improves outcomes for mechanically ventilated patients using its breakthrough, non-invasive, respiratory muscle-protective, neurostimulation device, VentFree.
  • Limbix, headquartered in Palo Alto, has a mission to improve mental health with accessible technology.
  • Nua Surgical, from Galway, Ireland, Nua Surgical is an award-winning Irish start-up dedicated to innovating in women’s health.
  • Houston-based Prana Thoracic is developing solutions for the detection and intervention of early-stage lung cancer.
Unlike past awards programs hosted by Ignite Healthcare Network, the Ignite Madness winners accepted their awards via video call. Photo courtesy of Ignite

Houston female-focused health tech pitch competition names big winners

winner, winner

From the comfort of their own homes, several female entrepreneurs accepted investment and pitch prizes at the finals of an inaugural awards program created by a Houston-based, woman-focused health organization.

Ahead of the Ignite Madness finals on Thursday, October 29, Houston-based Ignite Healthcare Network named nine finalists that then pitched for three investment prizes. The finalists included:

  • Eden Prairie, Minnesota-based Abilitech Medical — medical device company that creates assistive devices to aid those with upper-limb neuromuscular conditions or injuries.
  • New Orleans, Louisiana-based Chosen Diagnostics — a biotech company focusing on custom treatment. First, Chosen is focused on creating two novel biomarker diagnostic kits — one for gastrointestinal disease in premature infants.
  • San Francisco, California-based Ejenta — which uses NASA tech and artificial intelligence to enhance connected care.
  • Highland, Maryland-based Emergency Medical Innovation — a company focused on emergency medicine like Bleed Freeze, a novel device for more efficiently treating nosebleeds.
  • Columbia, Missouri-based Healium — an app to quickly reduce burnout, self-manage anxiety, and stress.
  • Farmington, Connecticut-based Nest Collaborative — digital lactation solutions and support.
  • Palo Alto, California-based Nyquist Data — a smart search engine to enable medical device companies to get FDA approvals faster.
  • New Orleans-Louisiana based Obatala Sciences — a biotech startup working with research institutions across the globe to advance tissue engineering and regenerative medicine.
  • Perth, Australia-based OncoRes — a company that's developing a technology to provide surgeons with real-time assessment of tissue microstructure.
The inaugural event that mixed health care and basketball — two vastly different industries with strong connections to women — attracted support from partners and sponsors, such as Intel, Accenture, Morgan Lewis, Houston Methodist, Johnson & Johnson Innovation, and more, according to Ayse McCracken, founder and board chair of Ignite.

"Our partners and sponsors are an integral part of our organization" says McCracken. "Without each and every one of them, the networks, resources, and commitment to advancing women leaders, we would not have grown so rapidly in just four years and our IGNITE Madness event would not enjoy this vibrant ecosystem that now surrounds female entrepreneurs."

First up in selecting their winner for their investment was Texas Halo Fund. Chosen Diagnostics took home the $50,000 investment.

"While we were impressed by everyone who pitched tonight, one company stood out to us," says Kyra Doolan, managing partner. "[Chosen Diagnostics] exemplifies what we are looking for: an innovative solution, a strong CEO, and a real addressable market."

The second monetary award was presented by Tom Luby, director of TMC Innovation. The award was an $100,000 investment from the TMC Venture Fund, as well as admission to TMCx. The recipient of the investment was OncoRes.

"We are absolutely blown away," says Katharine Giles, founder of Onco. "We've already got a great link to Texas and looking forward to more."

The largest monetary award that was on the table was presented by Wavemaker Three-Sixty Health, a leading Southern-California based, early stage venture capital firm, for $150,000. However, at the time of the announcement, Managing Partner Jay Goss decided to award four startups an undisclosed amount of investment. Goss says he and his team will meet with each company to establish an investment.
The companies that were recognized by Wavemaker were: Healium, Ejenta, Emergency Medical Innovation, and Nest Collaborative.
Lastly, Ignite itself had $27,500 cash awards to give out to the pitch competition winners. The funds will be distributed between the winners. OncoRes took first place, Abilitech came in second place, and Obatala Sciences took third place.
Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

4 Houston health tech startups advancing medical innovation

meet the finalists

Houston has been driving medical innovation for decades. And thanks to leading hospitals, cutting-edge research and breakthrough technologies, the region’s healthcare ecosystem continues to improve how patients are diagnosed, treated and cared for.

The Health Tech Business category in our 2025 Houston Innovation Awards will honor an innovative startup within the health and medical technology sectors.

Four forward-thinking businesses have been named finalists for the 2026 award. This year's finalists, selected by our esteemed panel of judges, range from a startup developing miniaturized medical technologies for space to a company using AI to help develop cancer treatment plans.

Read more about these businesses, their innovative founders, and how they're shaping the future of health care below.. The 2026 winners will be announced on InnovationMap.com in mid-November.

Bairitone Health

Bairitone Health is bringing anatomy imaging for sleep apnea to the home environment. The company's platform maps users' anatomy during natural sleep using a facial patch to determine the root cause of airway obstruction. It then offers effective therapies for each patient.

The company was founded in 2022 in the Texas Medical Center's Biodesign program by CEO Meagan Pitcher, CTO Onur Kilic and chief medical officer Britt Cross. It was a member of Activate Houston's inaugural cohort and has participated in numerous accelerators and incubators. The company raised an oversubscribed seed round for $2.4 million earlier this year and received Breakthrough Device Designation from the Food and Drug Administration in April.

InformAI Inc.

InformAI Inc. develops fit-to-purpose AI solutions for the clinical setting. Its RadOncAI product recently received FDA 510(k) clearance. The product uses AI to create a first-pass radiation therapy dose plan for complex head and neck cancers in an effort to eliminate bottlenecks in radiation planning and ultimately cancer treatment. The company has also developed AI products for sinus disease detection and 3D organ reconstruction.

CEO Jim Havelka founded the company in 2017. It is participating in the Mayo Clinic Accelerate Platform. It has raised about $4 million in seed funding and has received numerous non-dilutive grants from the National Science Foundation, the National Institutes of Health and the Cancer Prevention and Research Institute of Texas. The company shared in its application that it plans to launch a Series A fundraising round and submit an FDA 510K application for its organ reconstruction product, Voluquant, by the end of 2026.

Prana Surgical

Prana Surgical is developing a minimally invasive surgical platform for small, hard-to-reach lung nodules that may be cancerous. The company's Prana System cleared U.S. Food and Drug Administration (FDA) approval earlier this year.

Prana Surgical was originally founded as Prana Thoracic in 2022. It has participated in numerous accelerators, including the Texas Medical Center Innovation Accelerator in 2023 and the IGNITE Health accelerator in 2022. It raised $6 million in Series A funding rounds in 2023 and 2024 , with a Series B currently ongoing. The company said in its application that it is currently moving into the next stage of clinical validation and revenue generation in the U.S., in addition to preparing its manufacturing and commercial infrastructure for broader use.

Skybound MedTech

Skybound MedTech develops technologies that aim to address the health risks of long-duration spaceflight. Its compact, miniaturized medical technologies can deliver complex therapies without a physician.

CEO Matthew Kuhn, who previously founded Taurus Vascular, founded Skybound last year. The company emerged from stealth in January after raising a $1.25 million Series A round. It plans to advance its lead dual-use platform into critical preclinical validation in November, the company shared in its application. It is currently raising a $25 million Series A round and is pursuing federal research partnerships with DARPA and ARPA-H.

Generation Park lands new facility to scale xeno-organ production

Organ innovation

Maryland-based United Therapeutics Corp. has opened a new 77,448-square-foot facility to manufacture xeno-organs in Northeast Houston’s growing biotech hub, Generation Park.

The new Houston location is United Therapeutics’ third Designated Pathogen-Free (DPF) site, named for transplant pioneers Dr. Bartley P. Griffith and Dr. Robert A. Montgomery. The company says the new facility will enable it to scale commercial production of its xeno-organs once they receive regulatory approval.

An existing DPF facility in Virginia is supporting clinical trials for the xeno-organs, and a third site in Minnesota will also focus on commercialization with the Houston site, according to the company.

Xeno-organs are organs taken from a non-human animal source and transplanted, implanted or infused into a human recipient.

Currently, United Therapeutics is advancing clinical trials to support a Biologics License Application with the U.S. Food and Drug Administration for its investigational-stage xenotransplantation, UKidney, UThymoKidney and UHeart products. The products all involve working with the genes from humans and pigs.

In 2025, Chron.com reported the company was working to construct an estimated $96 million facility to breed genetically engineered animals. Head of investor relations at United Therapeutics Dewey Steadman told the Houston Business Journal in 2025 that the pigs’ DNA will be edited. In November 2024, a 53-year-old woman in Alabama received a transplanted kidney from UKidney that had 10 gene edits. She had the transplant removed in April 2025, after her body rejected it.

The Dr. Bartley P. Griffith and Dr. Robert A. Montgomery Xenograft Production Facility requires a “strictly controlled, biosecure barrier environment, including air filtration, filtered water, filtered feed supplies, and state-of-the-art decontamination entryways,” according to the company. Being pathogen-free means it includes calibrated air and water conduits to support the transplantability of xenograft products and to prevent contamination. For energy considerations, the building also features solar arrays.

“With our third xenograft production facility now open and clinical trials underway, United Therapeutics is moving closer to its goal of providing transplantable organs to the people who need them,” Martine Rothblatt, chairperson and CEO of United Therapeutics, said in a news release. “It is fitting that this facility is named for Dr. Griffith and Dr. Montgomery, whose first-in-human surgeries turned xenotransplantation from a theoretical possibility into a clinical reality.”

The facility, which wrapped construction in August, is located at 11848 Common Dock Dr. in Generation Park, which will house manufacturing sites for pharmaceutical heavyweights Bristol Myers Squibb and Eli Lilly. Last fall, Eli Lilly tapped Generation Park for its $6.5 billion manufacturing plant, and Bristol Myers Squibb made a $2.3 billion investment in August to bring its state-of-the-art site to the master-planned commercial district.

Elon Musk's SpaceX reports profit as AI and satellite businesses booms

Booming Business

SpaceX reported a bigger quarterly profit than expected on Tuesday, October 20, as its satellite communications and artificial intelligence businesses boomed.

The company, run by Elon Musk, posted a profit for the three months through September 2026 of $4.4 billion, or 35 cents per share, reversing a year-ago loss and easily topping Wall Street's expectations. Revenue soared to $14.6 billion, up 161%.

On a conference call with analysts, Musk suggested a merger with his electric car company Tesla might be in the works, something that has been rumored for months. He said both companies formed “special committees” of independent directors to discuss the issue, though he played down the chances of an imminent deal.

“Some people out there assume that a SpaceX and Tesla merger is a certainty,” he said. “I think that would be overstating it.”

The AI business became SpaceX's largest by revenue in the third quarter, although the Starlink satellite service remains the biggest profit generator.

“They beat across all metrics and the Starlink business looks to be accelerating,” said Dan Ives, an analyst at Yorkville Ives. “This is just what (Wall) Street wanted.”

The stock rose 7.5% in after-hours trading.

Musk also told analysts that for next month's launch of its Starship rocket, SpaceX will attempt to grab both the booster and ship with mechanical arms upon return to base, a key step toward demonstrating it can reuse the massive spacecraft.

“The only way that we can extend consciousness beyond Earth on a sustained basis is with a fully reusable orbital launch vehicle,” Musk said, calling the attempt, if successful, “a massive technology milestone.”

SpaceX hopes to get Starship on a regular launch pattern in preparation for NASA's upcoming lunar missions.

The company already has huge contracts with the federal government, and House Democrats have called for investigations into those contracts and Musk’s work with the Department of Government Efficiency. Musk has spent $276 million since July in support of Republican candidates.

In a filing for its initial public offering in June, SpaceX warned that a change in control of Congress could have a “material and adverse impact on our growth and competitive position.”

Musk recently drew criticism from politicians in Washington after speeds for a military version of SpaceX's satellite communications service were slowed for Ukraine following President Donald Trump's deal to get more diesel oil from Russia amid a push to end the war. The Wall Street Journal reported Tuesday that it was Musk who ordered the slowdown, impeding Ukraine’s use of drones along the front. SpaceX did not immediately respond to an Associated Press request for comment on the Journal story.

Both Trump and Musk have denied responsibility for the slowdown.

As midterm elections near, Musk on Monday promised to give one share of SpaceX to “every kid in America” next year, though he provided no details on how the distribution would be carried out. With communities nationwide protesting the construction of large data centers and concerns about AI safety, AI companies are trying to build goodwill. Anthropic pledged to commit 5% of its shares to a new “public benefit” fund.

SpaceX shares have been under pressure over concerns that the company was spending too much on major projects to compete with rivals such as Anthropic. The company said capital expenditures totaled $19.6 billion last quarter, nearly triple the figure from a year earlier, and it forecast spending would grow to $35 billion to $40 billion in the current quarter.

Shares of SpaceX closed Tuesday at $147.79, down from a peak near $201 after its IPO, which made Musk the world’s first trillionaire at the time. But the share prices for SpaceX and Tesla have since dropped, reducing his net worth to $925 billion, according to Forbes magazine.

Tesla reports third-quarter financial results Wednesday. Last week, Tesla unveiled a new Roadster sports car that in some versions may include thrusters allowing it to briefly fly using SpaceX technology — though experts say anything usable for drivers is a long shot.

View All Listings